Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
=== Inhalation === Airborne MNPs originate from urban dust, rubber tires, household plastic items, and synthetic fibers from textiles. It is also theorized that particles that have entered our waterways can become suspended in the air via wave action, as well as via the spreading of wastewater treatment sludge on agricultural fields. Once inhaled, these particles may become lodged in the lungs or, through mucociliary clearance, be ingested and enter the digestive system. Airborne microplastics have been detected in urban atmospheres, with reports showing a fallout of 29–280 particles per square meter per day on an urban rooftop, underscoring the potential for routine exposure. Annual inhalation exposure rates vary, with some studies estimating individuals inhale up to 68,000 particles each year. Children are at higher risk of exposure to MNPs by inhalation. When compared to adults, children have less efficient nasal filtering, are more typically mouth breathers, and breathe more air per unit of body mass. This makes them more susceptible to air pollutants of all kinds.
==== Wounds healing ==== For abrasions and wounds, nanochemistry has demonstrated applications in improving the healing process. Electrospinning is a polymerization method used biologically in tissue engineering but can also be used for wound dressing and drug delivery. This produces nanofibers that encourage cell proliferation, antibacterial properties, in controlled environment. These properties appear macroscopically, however, nanoscale versions may show improved efficiency due to nanotopographical features. Targeted interfaces between nanofibers and wounds have higher surface area interactions and are advantageous in vivo. There is evidence that certain nanoparticles of silver are useful to inhibit some viruses and bacteria.
Modified castor oil - much like cellulose, castor oil has hydroxyl groups, unlike other oils which at most have double bonds, which castor oil also has, but most substitutions occur at the hydroxyl moieties, allowing exotic derivatives with myriad properties. The most recent advances in rheology modifiers have been in this category. The BASF corporation has a new line based on castor oil derivatives, for example. Organosilicones - Silicone resins, dimethicones, and modified silicones simplify formulation somewhat, a borrowing from cosmetics. All of the above rheology modifiers are used in the 0.2% to 2.0% range
On 1 July 2016, Townsend joined Premier League club Crystal Palace on a five-year contract from Newcastle following their relegation to the Championship. Palace triggered his £13 million release clause just six months after he joined from Tottenham. He was originally assigned the number 17 shirt for his first season with Palace. However, after Yannick Bolasie left for Everton, Townsend was reassigned the vacant number 10 shirt previously worn by Bolasie. On 13 August 2016, Townsend made his debut in a 1–0 defeat against West Bromwich Albion in the Premier League. He scored his first goal for the club in a 4–1 victory over Stoke City in the league on 18 September. On 22 December 2018, Townsend scored a 30-yard volley in a 3–2 league win against Manchester City. His strike was later voted as Premier League Goal of the Month for December and Premier League Goal of the Season, as well as making the shortlist for the 2019 FIFA Puskás Award. In June 2021, Townsend was announced to be one of the players released by Crystal Palace at the end of the 2020–21 season, ending his five-year tenure with the side.
Sources: en.wikipedia.org
== Applications == Fluorine-18 is one of the early tracers used in positron emission tomography (PET), having been in use since the 1960s. Its significance is due to both its short half-life and the emission of positrons when decaying. A major medical use of fluorine-18 is: in positron emission tomography (PET) to image the brain and heart; to image the thyroid gland; as a radiotracer to image bones and seeking cancers that have metastasized from other locations in the body and in radiation therapy treating internal tumors. Tracers include sodium fluoride which can be useful for skeletal imaging as it displays high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ratio in a short time and fluorodeoxyglucose (FDG), where the 18F substitutes a hydroxyl. New dioxaborolane chemistry enables radioactive fluoride (18F) labeling of antibodies, which allows for positron emission tomography (PET) imaging of cancer. A Human-Derived, Genetic, Positron-emitting and Fluorescent (HD-GPF) reporter system uses a human protein, PSMA and non-immunogenic, and a small molecule that is positron-emitting (18F) and fluorescent for dual modality PET and fluorescence imaging of genome modified cells, e.g. cancer, CRISPR/Cas9, or CAR T-cells, in an entire mouse. The dual-modality small molecule targeting PSMA was tested in humans and found the location of primary and metastatic prostate cancer, fluorescence-guided removal of cancer, and detects single cancer cells in tissue margins.
Amino Acid + ATP + tRNA → Aminoacyl-tRNA + AMP + PPi The net reaction is energetically favorable only because the pyrophosphate (PPi) is later hydrolyzed. The hydrolysis of pyrophosphate to two molecules of inorganic phosphate (Pi) reaction is highly energetically favorable and drives the other two reactions. Together, these highly exergonic reactions take place inside the aminoacyl-tRNA synthetase specific for that amino acid.
Chemicals added during crusting must be fixed in place. Crusting culminates with a drying and softening operation, and may include splitting, shaving, dyeing, whitening or other methods. For some leathers, tanners apply a surface coating, called "finishing". Finishing operations can include oiling, brushing, buffing, coating, polishing, embossing, glazing, or tumbling, among others. Leather can be oiled to improve its water resistance. This currying process after tanning supplements the natural oils remaining in the leather itself, which can be washed out through repeated exposure to water. Frequent oiling of leather, with mink oil, neatsfoot oil, or a similar material keeps it supple and improves its lifespan dramatically.
Sources: en.wikipedia.org
=== Lawsuit === Fenn's work with electrospray ionization was at the center of a lawsuit pitting him against his alma mater and former employer, Yale University. His initial dispute with the university began in 1987, when he turned 70 – Yale's mandatory retirement age. Per university policy, Fenn was made an emeritus professor, which resulted in a reduction to his lab space. Emeritus professors at Yale are still provided with an office, but cannot conduct their own research, nor manage their own labs. In 1989, when Yale University inquired about the progress and potential about his electrospray work, he downplayed its potential scientific and commercial value. Fenn believed he had the rights to the invention under the Bayh–Dole Act. Fenn patented the technology on his own, and sold licensing rights to a company he partly owned – Analytica of Branford. In 1993, a private company seeking to license the use of electrospray technology traced its invention to Yale, when the university discovered that Fenn held the patent. Yale's policy regarding patents generated by faculty or students requires that a percentage of any royalties generated from the patent are used by the university to fund future research. They do not claim the rights to patents that are produced away from university facilities or not related to the researcher's "designated activities." Fenn claimed that he owned the technology because the work was completed after he had been forced to downsize at the university's mandatory retirement age.
Sean Kinney said about the band's reunion: I never called Jerry; he never called me, and said, 'Hey, let's get the band back together,' you know? We had been taking every step extremely cautious and slow, and just doing whatever feels right: If it's genuine and we're doing it for genuine reasons and we're all okay with it then we take a little step. None of us is broke. Nobody needs to be a rock dork, and you know, stroke their ego. I mean, we don't really operate like that. So as long as it felt good and from the right place and it's about making music and carrying on... About the pressure being put on DuVall for replacing Staley as lead vocalist, Cantrell said, To put all that weight on Will's shoulders is unfair. We're just figuring out how we work as a team. Although the band has changed, we've lost Layne, we've added Will, and there was no master plan. Playing again in 2005 felt right, so we did the next thing and toured. We did it step by step. It's more than just making music, and it always has been. We've been friends a long time. We've been more of a family than most, and it had to be okay from here [pointing to his heart]. Former The Doors manager Bill Siddons and his management company, Core Entertainment, co-managed Alice in Chains with original manager Susan Silver from 2005 to 2007. The band started writing and demoing songs for a new album with DuVall in April 2007. But the band did not show further signs of progress until October 2008, when they announced that they had begun recording with producer Nick Raskulinecz in the studio.
=== Iodine === Iodine sublimes gradually and produces visible fumes on gentle heating at standard atmospheric temperature. It is possible to obtain liquid iodine at atmospheric pressure by controlling the temperature at just between the melting point and the boiling point of iodine. In forensic science, iodine vapor can reveal latent fingerprints on paper.
== Dimer alkaloids == In addition to the described above monomeric alkaloids, there are also dimeric, and even trimeric and tetrameric alkaloids formed upon condensation of two, three, and four monomeric alkaloids. Dimeric alkaloids are usually formed from monomers of the same type through the following mechanisms:
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.